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In March 2020, the world was hit by a perfect storm: the 
COVID-19 pandemic. Already in 1994, Laurie Garrett made a 
case for “newly emerging diseases in a world out of balance”, 
expressing concern about the appearance of new infectious 
diseases. More recently, many other thoughts and warnings 
were expressed on this topic, for example by Bill Gates in his 
2015 TED Talk. And now it is happening, shaking the very 
foundations of our society and economy. The outbreak of the 
Wuhan Coronavirus (COVID-19) disease has transformed the 
world as we know it into a new normal – a kind of a brave new 
world 2.0 – disrupting the business models of civil society, 
(higher) education, world economy, business, governments, 
policies. It is clear – we are on the eve of a paradigm shift, and 
it is up to us whether we will influence it or simply allow it to 
happen, not only in science-knowledge but also in human 
interactions and behavior, basically all aspects of our up-to-now 
comfortable life.  
Disruption came in a different shape and form. This article 
discusses the impact of the COVID-19 pandemic on a number 
of selected and strategic industries 
 




1.  INTRODUCTION 
 
"I think there are good reasons for suggesting that the modern 
age has ended. Today, many things indicate that we are going 
through a transitional period, when it seems that something is 
on the way out and something else is painfully being born. It is 
as if something were crumbling, decaying, and exhausting itself, 
while something else, still indistinct, were arising from the 
rubble."  
Vaclav Havel (1994) 
 
In March 2020, the world was hit by a perfect storm: the 
COVID-19 pandemic. Already in 1994, Laurie Garrett made a 
case for “newly emerging diseases in a world out of balance”, 
expressing concern about the appearance of new infectious 
diseases. More recently, many other thoughts and warnings were 
expressed on this topic, for example by Bill Gates in his 2015 
TED Talk. And now it is happening, shaking the very 
foundations of our society and economy. The outbreak of the 
Wuhan Coronavirus (COVID-19) disease has transformed the 
world as we know it into a new normal – a kind of a brave new 
world 2.0 – disrupting the business models of civil society, 
(higher) education, world economy, business, governments, 
policies. It is clear – we are on the eve of a paradigm shift, and it 
is up to us whether we will influence it or simply allow it to 
happen, not only in science-knowledge but also in human 
interactions and behavior, basically all aspects of our up-to-now 
comfortable life. 
The COVID-19 pandemic can be cataloged as a so-called “Black 
Swan”: a random event that underlies almost everything about 
our world and our personal lives. A black swan is a highly 
improbable event, unpredictable and carrying with it a massive 
impact (Taleb, 2007) [20].  
 
Recovering from Covid-19 put our economic systems to the test. 
According to Chesbrough (2020), innovation will have an 
important role to play. Innovation is often analyzed in terms of 
costs. In the case of an unpredictable pandemic, time is so 
valuable and essential that the question of costs is far less 
important than the ability to get to a solution sooner. The global 
impact was far stretched and quickly visible with: 
− slowed economies and societies; 
− affected financial markets; 
− decreased revenues for businesses and industries; 
− disturbed global supply chains. 
The multilevel theory of national competitive advantage of 
industries and nations (Porter, 1990) [13] focuses on why certain 
industries within a nation are competitive internationally. Porter 
argues that the competitive advantage of certain industries in 
different nations depends on a dynamic interaction of four 
aspects as illustrated below in his “diamond model”, connecting 




Fig. 1: The Competitive Advantage of Nations – Diamond 
Model (Porter, 1990) [13] 
 
2. CREATIVE DESTRUCTION  
 
Creative Destruction (Schumpeter, 1942) [17] is an 
evolutionary process within capitalism that “revolutionizes the 
economic structure from within, incessantly destroying the old 
one, incessantly creating the new one” (Pfarrer & Smith, 2005) 
[12]. Innovation and entrepreneurship occupy a decisive role for 
economic development, even more in times of crisis. The 
entrepreneur is the central player in the market process. The 
successful firm must constantly be innovating to sustain 
profitability and to avoid the “perennial gale” of Creative 
Destruction. According to Schumpeter (1942) [17], large, 
established enterprises play the role of innovative leaders. 
Creative destruction refers to the phenomenon of economic 
change through the creation of new ways of doing things that 
endogenously destroy and replace the old ways. The term 
“creative destruction” is usually used to emphasize the dynamic 
nature of the modern economic system. According to 
Schumpeter, entrepreneurs initiate gales of creative destruction 
and therefore destroy existing equilibriums. Creative destruction 
results from challenges by disruptive technology (Kessler, 2013) 
[9]. 
Disruptive innovation means that speed is important to create 
and sustain competitive advantage of firms amidst rapidly 
changing business environments. The phenomenon of disruption 
was coined in the mid-1990s (Christensen, 1997; Christensen et 
al., 2018; Schmidt and Herting, 2020) [6],[7],[16], showing how 
new entrants challenge established organizations – incumbents – 
by introducing new offerings, which develop along an 
alternative performance trajectory.  
Disruptive technologies are commercialized in niches of markets 
but they can penetrate mainstream markets and compete with 
incumbent technologies. Christensen (1997) [5] observes that 
established firms face an “innovator’s dilemma” that is 
associated with internal resource-allocation processes leading 
them to systematically underinvest in disruptive technologies. 
The lack of business model innovation is the main reason for 
incumbents being disrupted. Many current cases across 
industries show how business models affect disruptive change in 
established industries (Christensen et al., 2018) [6].  
 
Fig. 2: From Creative Destruction to Creative Disruption 
(Segers, 2020) 
 
Creative disruption is synonymous with creativity, challenge 
and change. The aims of creative disruption include creating 
new business innovations that lead to new markets – i.e. impact 
of emerging technologies – and new marketing techniques. 
In the next section, a number of selected and strategic industries 
are explored, drawing on the concepts of multiple case study 
research design (Yin, 2009; 2012) [23], [24] and the use of 
secondary qualitative data. The multiple case study research 
method is widely used for examining technology and innovation 
adoption issues.  
The proposed industries are: 
1. the civilian aerospace and defense industry, in 
particular the case of Airbus Group (Airbus 
Industries) [1], [2]; 
2. the biopharmaceutical industry; 
3. Big tech.  
 
3. DISCUSSION OF SELECTED AND STRATEGIC 
INDUSTRIES 
 
Civilian aerospace and defense industry: the Airbus case. 
Airbus began operation in 1970 (Blagnac, France) and quickly 
became a powerful symbol of what can be achieved by 
European political and economic cooperation (McGuire, 1997) 
[10]. The company, formally known as the European Aeronautic 
Defence and Space Company (EADS) is a civilian aerospace 
and defence consortium that connected Aérospatiale-Matra 
(France), DASA (Germany), Construcciones Aeronáuticas 
(Spain) and British Aerospace (the United Kingdom). From the 
European perspective, Airbus was an entirely appropriate 
response to the United States dominance in the global market for 
commercial aircraft, its main competitor being Boeing. Airbus 
has risen to a position where it now has a 50-50 split of the 
global market with Boeing. Airbus is thus a good illustration of 
how European nations can work together to compete 
strategically on the international stage (see Porter’s diamond 
model discussed earlier). 
Over the last decades, Airbus has become the orchestrator in the 
leading European aerospace ecosystem with many European 
subcontractors, e.g., in Belgium (Segers, 2017a) [18]. Without 
related and supporting industries such as engines, avionics and 
materials, a key industry such as aerospace cannot become 
globally competitive. It is this that made it possible for Airbus to 
succeed.  
An interesting evolution is the way Airbus has moved toward 
open innovation (Segers, 2017a; Airbus, 2020) [18], [1], [2]. 
with greater use of outsourcing in their business models (Saias 
and Kapadia, 2016) [14]. The aerospace industry is 
characterized by so-called value chain deconstruction: a focus 
on core business-critical competencies, together with the 
outsourcing of non-core activities. The outsourcing 
arrangements allow them to gain access to technology 
specialists that help them make the most of new innovations 
and models.  
Airbus is enhancing its innovation process through the 
operation of a global network of accelerator facilities – called 
Airbus BizLabs (2020) [1], [2] – to speed up the 
transformation of ground-breaking ideas into valuable 
business propositions, all within an extended innovation 
ecosystem. This set-up has two primary methods for meeting 
its goal:  
• accelerating the pace at which Airbus 
commercializes its own innovations;  
• drawing upon and developing more ideas from 
outside Airbus, including customers and 
companies from other business sectors. 
Another important feature is the use of subsidies by Airbus – the 
so-called government shelter – through extensive subsidization 
in public private partnerships (see Fig. 3).  
Together with competitive product matching towards Boeing, 
this represents an interesting example of a company preparing 
itself strategically for moving beyond government shelter 
(Sarathy, 1994) [15]. 
 
 
Fig. 3: The Airbus PPP (Segers, 2020) 
 
And like so many industries, Airbus is now facing multiple 
emerging global issues such as climate change and 
sustainability, technological disruption, the current COVID-19 
pandemic and an evolving competitive landscape with new 




The COVID-19 pandemic undermines the world economy and 
our health systems. The principles of disruptive innovation are 
applicable to the healthcare sector as it can improve both 
affordability and accessibility in healthcare so that more 
people get the care they need. The biopharmaceutical industry 
within biotech clusters around the world are more than ever 
considered as strategic industries in many countries. They are 
the driving forces of the economy and for global healthcare, as 
measured by R&D-intensity, the level of patent applications, 
the number of drugs in the pipeline, venture capital invested 
and the number of new biotechnology firms (Segers, 2017b) 
[19]. 
The first and most important task today is to defeat the 
invisible enemy – the coronavirus. The COVID-19 pandemic 
is reshaping the way companies collaborate and innovate. It 
triggered an unprecedented and intense level of global R&D 
activity and collaboration by research teams in companies and 
universities across the world in the search for vaccines. As of 
July 2020, 160 vaccines – this number is constantly rising 
(World Health Organization (2020); Callaway (2020)[3] – are 
being developed against SARS-CoV-2, the coronavirus that 
causes COVID-19: 
− 21 candidate vaccines in clinical evaluation; 
− 139 candidate vaccines in preclinical evaluation. 
Some clinical trials involve next-generation vaccine 
technology platforms which have never been used in a 
licensed vaccine before.  
Leading pharmaceutical and biotechnology companies like 
Johnson & Johnson (Janssen), Pfizer-BioNTech, Merck & Co, 
the Sanofi-GSK alliance, Gilead, Moderna Therapeutics, 
Inovio Pharmaceuticals, together with research universities 
and hospitals (e.g., the alliance of Oxford University 
Hospitals, Oxford Biomedica and AstraZeneca), governments 
and broader international scientific community are working 
together in public private partnerships (PPP) like never before 
to produce a coronavirus vaccine (see Fig. 4).  
 
 
Fig. 4: Profile of COVID-19 vaccine developers (PPP) - 
Thanh Le, et al. (2020) [21]. 
 
Pharmaceutical and biotechnology companies and clinical 
research organizations are taking the race to the limit to 
develop a coronavirus vaccine, simultaneously waking the 
general public up to an important warning sign: the time of 
going from concept to marketable product, the time needed to 
produce vaccine. The pharmaceutical industry is stressing that 
the finish line is at least 12 to 18 months away. It hopes to 
compress the time to market distribution to within 2021 at the 
earliest, being significantly sooner than the 10 to 15 years the 
process of getting a new vaccine to market typically takes. 
The joint battle against the coronavirus creates new business 
models of cooperation and coopetition. It provides a 
momentum for new public private partnerships to shift the 
world we used to live in. COVID-19 poses an unprecedented 
challenge for big pharmaceutical and biotechnology 
companies which creates new possibilities and models for 
coopetition and demonstrates real open innovation and value 
co-creation opportunities and approaches. Coopetition and 
open innovation here mean that companies cooperate on life 
saving projects while maintaining the drive of competition in 
the long run, making the race to find both medicines and 
vaccines for the COVID-19 pandemic more efficient and 
effective. According to Thanh Le, et al. (2020) [21], it will be 
important to ensure coordination of vaccine manufacturing and 
supply capability and capacity to meet demand.  
Strategies of research alliances and acquisitions in the drug 
discovery industry may help incumbents to overcome inertia 
both in the initial stage of research and in the later stage of 
development of disruptive technologies (Coccia, 2020) [8]. 
Although the R&D competition remains as fierce as ever 
before, given this “normal” business model, a number of 
public private partnerships for the financing of clinical studies 
and the enhancement of production capacity worldwide have 
been speeded up. Some good practices are: 
− finance independent research projects to develop 
vaccines against emerging infectious diseases; 
− GAVI, the Vaccine Alliance. Its public-private 
business model draws on the skills and strengths of 
its core partners like the World Health Organization, 
UNICEF, the World Bank and the Bill & Melinda 
Gates Foundation. Gavi and its Alliance partners are 
providing immediate funding to health systems and 
enabling countries to purchase diagnostic tests; 
− EFPIA, the research-based pharmaceutical 
industry in Europe, launching clinical development 
of potential vaccines against the coronavirus; 
− IMI, the Innovative Medicines Initiative: the 
development of therapeutics and diagnostics to 
tackle current and future coronavirus outbreaks 
(drug development and repurposing); 
− government-led consortia of pharma, biotech, IT 
and academia, e.g., in Belgium; 
− open government approaches to tackling COVID-
19 (Mention, 2020) [11], building trust between 
government and citizens, digital platforms or apps; 
− Operation Warp Speed in the United States, a 
national program with the Biomedical Advanced 
Research and Development Authority (BARDA) to 
accelerate the development, manufacturing, and 
distribution of COVID-19 vaccines, therapeutics, 
and diagnostics; 
− The Accelerating COVID-19 Therapeutic 
Interventions and Vaccines (ACTIV) partnership, 
i.e. a public-private partnership to speed COVID-19 
vaccine and treatment options by the National 
Institutes of Health in the United States. It brings 
together more than a dozen leading 
biopharmaceutical companies, the Food and Drug 
Administration and the European Medicines Agency 
to develop an international strategy for a coordinated 
research response to the COVID-19 pandemic.  
 
Big Tech  
It’s crucial that our economies embrace innovation and thus 
create societal and business value. We live in a time frame that 
is commonly referred to as the 4th industrial revolution. Many 
powerful new technologies and platforms have emerged (Fig. 
5). Industry 4.0 relies on the cloud, internet of things (IoT), big 
data, 3D printing (additive manufacturing), artificial 
intelligence, augmented reality, virtual reality, blockchain and 
drone technology. Accordingly, industry 4.0 is about product 
development, manufacturing, supply chain and new business 
models for future growth (Treves and O’Shea, 2020) [22]. 
 
 
Fig. 5: Emerging Technologies (Gartner) [26] 
 
The COVID-19 pandemic created a new and crucial 
momentum for these technologies and platforms. The world is 
in need of a rapid development and manufacture of critical 
personal protective equipment, testing material and 
diagnostics, access to vaccines, ventilators for the intensive 
care units, mouth masks, etc. In line with the sense of urgency, 
digital healthcare (e-health) and medtech, the use of big data 
and artificial intelligence are booming. COVID-19 thus 
strengthens big tech companies like Facebook, Amazon, 
Apple, Microsoft and Google. 
At the same time, big manufacturing companies like General 
Motors, Ford and Tesla are forming partnerships with 
aerospace firms, ventilator manufacturers and others to 
transform some of their manufacturing capacity to assemble 
much needed critical equipment like ventilators and 
respiratory appliances and to boost output as fast as possible 
(Chesbrough, 2020) [4]. The world witnesses a time where 
well known startups and scaleups are now outperformed by 
big tech in a kind of reversed disruption.  
Artificial intelligence (AI) is disrupting value chains. 
According to the World Economic Forum (2018) [23], there 
are several distinct value propositions for AI in the creative 
economy. One disruption will undoubtedly come in the form 
of automation and augmentation of human creative processes. 
The same is happening with Blockchain technology which has 
grown in recent years. It is primarily seen as a platform for 
cryptocurrencies, but further applications are rapidly emerging 
when the technology is applied to other data structures, such as 
ownership and contract details. AI will allow to obtain or 
sustain a competitive advantage or to move into new 
businesses. 
COVID-19 has also stimulated the use of the 3D printing 
technology. Here also, universities and research centers are 
working closely together with new technology-based firms – 
high tech startups and scaleups. In Belgium, for example, the 
3D-printing ecosystem is introducing new innovative business 
models and working on disruptive possibilities of 3D printing 
technology for business and society. Additive manufacturing 
software solutions and sophisticated 3D printing services can 
be applied in a wide variety of industries, including healthcare 
(3D bioprinting of live stem cells; artificial implants, medical 
image processing, surgical simulations), automotive, 
aerospace, design and consumer products (Segers, 2017a) 
[18]. 
We live in a century of robots, with a fast-growing subfamily 
called drones. The development of commercial drone 
applications in close partnership with other emerging 
technologies such as artificial intelligence is again a good 
example of COVID-19 enhanced innovation, e.g., with respect 





In terms sectors affected by COVID-19 one can mention 
tourism and transport - especially aviation. Due to the virus, we 
can observe both the closure of factories, prolongation of the 
delivery time of production to markets, shaking of financial 
markets etc.  All areas are affected.  
COVID-19 is a catalyst for change in all industries and gives 
unexpected stimulus for innovation development 
This is obvious – world is going through a transitional period – 
society is breaking old habits and agreements with an aim to 
speed up movement to the future. Not all changes are equal or 
easy to make. It tackles all elements – financial, technical, 
human… some elements are easy to change, some not. It is time 
to break old corporate habits, adapt and improve, and create 
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